Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06420063

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML (BAH244)

Sequential CAR-T Cell Infusion Targeting CD33 and CD123 for Refractory/Relapsed Acute Myeloid Leukaemia

Sponsor: Essen Biotech

Conditions AML AML, Adult AML, Adult Recurrent Acute Myeloid Leukemia

Updated 5 times since 2024 Last updated: Nov 10, 2024 Started: Jul 10, 2024 Primary completion: Dec 10, 2025 Completion: Dec 28, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates AML and AML, Adult and is currently actively recruiting participants. Essen Biotech leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Dec 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Essen Biotech

Data source: Essen Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China